Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nurexone Biologic Inc (NRX.VN)

Nurexone Biologic Inc (NRX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Nurexone Biologic Inc 1 Adelaide Street East Suite 801 Toronto ON M5C 2V9 CAN

https://www.nurexone.com

Sector:

Medical

INDUSTRY GROUPING:

TSX Biotechnology

Description:

NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.

Key Statistics

Overview:

Market Capitalization, $K 61,663
Shares Outstanding, K 90,681
Annual Sales, $ 0 K
Annual Net Income, $ -5,043 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,465 K
60-Month Beta 0.58

Growth:

1-Year Return -21.79%
3-Year Return 83.78%
5-Year Return 0.00%

Per-Share Information:

Most Recent Earnings -0.02 on 11/26/25
Next Earnings Date N/A
Earnings Per Share ttm -0.08
EPS Growth vs. Prev Year 21.92%
Dividend Payout Ratio 0.00%

NRX.VN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -298.06%
Return-on-Assets % -208.79%
Profit Margin % 0.00%
Debt/Equity 0.02
Price/Sales N/A
Price/Book 30.69
Book Value/Share 0.02
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar